Scaling back the PI business and reallocating sales resources to the gastrointestinal field
First written in FY2023. 2 of 5 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AchievedAnnual report
「Revenue excluding the coronary intervention business, which ended in the previous consolidated fiscal year, was ¥597 million, up 34.6% year on year.」
It was confirmed that the CI business had been fully discontinued in the previous consolidated fiscal year. - FY2024-Q3AdvancedAnnual report
「In Other, revenue declined substantially, by 70.1% year on year. Sales of coronary intervention (CI)-related products, including the drug-eluting coronary stent “Orsiro,” declined substantially as the business was wound down, resulting in a 70.1% year-on-year decline in revenue.」
CI-related sales declined substantially as the business was wound down, resulting in a 70.1% year-on-year decline in revenue. The downsizing of the PI and CI businesses and the reallocation of resources to the gastrointestinal field are progressing. - FY2024-Q2RestatedAnnual report
「In Other, revenue declined 71.3% year on year as sales of coronary intervention (CI)-related products, including the drug-eluting coronary stent “Orsiro,” declined. The company has decided to withdraw from this business field and plans to end sales of CI-related products during the current consolidated fiscal year.」
The decision to withdraw from the CI-related business and the plan to end sales during the current consolidated fiscal year were reaffirmed. - FY2024-Q1AdvancedAnnual report
「In Other, revenue declined 65.2% year on year as sales of coronary intervention (CI)-related products, including the drug-eluting coronary stent “Orsiro,” declined. The company has decided to withdraw from this business field and plans to end sales of CI-related products during the current consolidated fiscal year.」
Following the downsizing of the PI business and reallocation of sales resources to the gastrointestinal field, the company decided to withdraw from the CI-related business and explicitly stated that sales are scheduled to end during the current consolidated fiscal year. - FY2023First statedAnnual report
「PI-related business, meaning percutaneous intervention, recorded a substantial decline in revenue as a result of downsizing the business and reallocating sales resources to the gastrointestinal field against a backdrop of intensifying competition and other factors.」
As a response to intensifying competition, the company downsized the PI business and explicitly disclosed for the first time a business portfolio change involving the reallocation of sales resources to the gastrointestinal field.